User login
Article Type
Changed
Fri, 01/04/2019 - 11:13
Display Headline
Elotuzumab and ixazomib join the therapeutic arsenal for multiple myeloma
Last year, 2015, was a banner year for multiple myeloma treatment, with 5 new drugs approved by the US Food and Drug Administration. Two of those drugs, the monoclonal antibody elotuzumab and the proteasome inhibitor, ixazomib, were approved in November, following promising phase 3 clinical trial results, in combination with standard multiple myeloma therapies, the immunomodulatory agent lenalidomide and the corticosteroid dexamethasone, in the second-line setting. Notably, the approval of ixazomib marks the availability of the first all-oral regimen for multiple myeloma.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 14(8)
Page Number
334-336
Legacy Keywords
elotuzumab, ixazomib, multiple myeloma, monoclonal antibody, proteasome inhibitor, immunomodulatory agent, lenalidomide, corticosteroid, dexamethasone
Sections
Article PDF
Article PDF
Last year, 2015, was a banner year for multiple myeloma treatment, with 5 new drugs approved by the US Food and Drug Administration. Two of those drugs, the monoclonal antibody elotuzumab and the proteasome inhibitor, ixazomib, were approved in November, following promising phase 3 clinical trial results, in combination with standard multiple myeloma therapies, the immunomodulatory agent lenalidomide and the corticosteroid dexamethasone, in the second-line setting. Notably, the approval of ixazomib marks the availability of the first all-oral regimen for multiple myeloma.
Click on the PDF icon at the top of this introduction to read the full article.
Last year, 2015, was a banner year for multiple myeloma treatment, with 5 new drugs approved by the US Food and Drug Administration. Two of those drugs, the monoclonal antibody elotuzumab and the proteasome inhibitor, ixazomib, were approved in November, following promising phase 3 clinical trial results, in combination with standard multiple myeloma therapies, the immunomodulatory agent lenalidomide and the corticosteroid dexamethasone, in the second-line setting. Notably, the approval of ixazomib marks the availability of the first all-oral regimen for multiple myeloma.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 14(8)
Issue
The Journal of Community and Supportive Oncology - 14(8)
Page Number
334-336
Page Number
334-336
Article Type
Display Headline
Elotuzumab and ixazomib join the therapeutic arsenal for multiple myeloma
Display Headline
Elotuzumab and ixazomib join the therapeutic arsenal for multiple myeloma
Legacy Keywords
elotuzumab, ixazomib, multiple myeloma, monoclonal antibody, proteasome inhibitor, immunomodulatory agent, lenalidomide, corticosteroid, dexamethasone
Legacy Keywords
elotuzumab, ixazomib, multiple myeloma, monoclonal antibody, proteasome inhibitor, immunomodulatory agent, lenalidomide, corticosteroid, dexamethasone
Sections
Citation Override
JCSO 2016;14:(8)334-33
Disallow All Ads
Alternative CME
Article PDF Media
Document